MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
9.58
+0.24
+2.57%
Pre Market: 9.63 +0.05 +0.52% 08:41 07/28 EDT
OPEN
9.64
PREV CLOSE
9.34
HIGH
9.91
LOW
9.58
VOLUME
25.29K
TURNOVER
0
52 WEEK HIGH
11.22
52 WEEK LOW
6.00
MARKET CAP
2.43B
P/E (TTM)
-5.3926
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCRX last week (0720-0724)?
Weekly Report · 1d ago
How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease Deals
Simply Wall St · 5d ago
BioCryst to report Q2 2026 results, host conference call and webcast
PUBT · 6d ago
Can BioCryst Pharmaceuticals (BCRX) Be Worth More As A New CSO Sharpens Its Pipeline Story?
Simply Wall St · 07/20 12:28
Weekly Report: what happened at BCRX last week (0713-0717)?
Weekly Report · 07/20 09:45
BioCryst Names David W. Jenkins Chief Scientific Officer To Drive Rare Disease Pipeline
NASDAQ · 07/15 13:32
BioCryst names David Jenkins chief scientific officer
PUBT · 07/15 11:03
*BioCryst Appoints David W. Jenkins as Chief Scientific Officer
Dow Jones · 07/15 11:01
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.